Meet Our Providers

Jamie K. Waselenko, MD, FACP, FICT

Medical Director and Founder

Dr. Jamie Waselenko (or Dr. Jamie as her patients call her) was born in Kentucky and raised in Michigan, where she graduated magna cum laude from Wayne State University in 1988. She then attended medical school while serving in the United States Army at the Uniformed Services University in Bethesda, MD. She is a Fellow of the American College of Physicians and holds professional associations in the American Society of Clinical Oncology, Alpha Omega Alpha Medical Honor Society, American Society of Hematology, American Academy of Anti-Aging Medicine, and the Institute of Functional Medicine.

Dr. Jamie then completed her internal medicine internship at Walter Reed Army Medical Center (WRAMC), her internal medicine residency at Madigan Army Medical Center, and her hematology and oncology fellowship at WRAMC. She received additional post-graduate training in translational research and bone marrow transplantation at Johns Hopkins Medical Center in Baltimore, MD. Dr. Jamie served at two of the Army's teaching hospitals, WRAMC and Brooke Army Medical Center in San Antonio, TX. She proudly served 17 years in the U.S. Army and thoroughly enjoyed caring for military beneficiaries.

After completing her service obligation, Dr. Jamie joined the research team at Sarah Cannon Research Institute and Tennessee Oncology to develop a leukemia program and lead a team to create a new stem cell transplant program. While there, she became the clinical director of the Sarah Cannon Blood and Marrow Transplant Program and the director of leukemia research at the Sarah Cannon Research Institute (SCRI). Dr. Jamie has conducted research and has publications focused on leukemia, lymphoma, stem cell transplantation, and acute radiation syndrome management. After leaving SCRI, Dr. Jamie went into private practice in 2007 and began working at the Christ Hospital (TCH) in Cincinnati, OH, in approximately 2011, when the practice was bought by the hospital.  She left private practice after 14 years to start her own telemedicine company and to assist in the care of hematology-oncology patients with complex illnesses in need of such services located in remote or resource-limited environments. During this time, Dr. Jamie acquired additional expertise in integrative oncology and functional medicine.

Dr. Jamie has over 28 years of clinical experience and is board-certified in medical oncology, hematology, and internal medicine. She offers a thorough, comprehensive approach in her practice to provide state-of-the-art care to patients with both blood disorders and cancer. She sees patients with all facets of blood and cancer diagnoses.

Dr. Jamie is founder and medical director of Cincinnati Integrative Oncology and Functional Medicine.  She has partnered with an amazing team that possesses the same degree of excellence in their respective fields and the same commitment to exceptional care for patients actively dealing with cancer or who are at risk of cancer recurrence or development.  Dr. Jamie now approaches ALL patients’ cases with a comprehensive, integrative approach in their cancer care or cancer-preventative strategy. She knows what your oncologist knows and doesn’t know!

PUBLICATIONS

• Wisdorf D, Chao N, Waselenko JK, Dainiak N, Armitage JO, McNiece I, Confer D.

• Acute radiation injury: contingency planning for triage, supportive care, and transplantation.
  Biol Blood Marrow Transplant. 12:672-82, 2006

• Waselenko J.K., Flinn I.W., Reese A, Lucas M, Park K, Goodrich A, Shinn C.A., Willis C.R., Morrison C, Diehl LF, Grever M.R, Byrd J.C. A phase I/II study targeting intrinsic biologic resistance factors employing theophylline, pentostatin, and chlorambucil in patients with relapsed lymphoproliferative disorders. Ann Hematol. 85:301-7, 2006

• Goans RE, Waselenko JK. Medical Management of Radiological Casualties, NCRP Annual Meeting 2004. Health Phys. 89:505-12, 2005

• Jackson, WL Jr., Gallagher C, Myhand RC, Waselenko JK.  Medical Management of Multiple System Organ Dysfunction Arising in Patients with Acute Radiation Injury. BJR Suppl. 27:161-8, 2005

• Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley A, Dickerson WE, Tsu H, Confer DL, Coleman CN, Armitage JO, Dainiak N. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Working Group. Ann Intern Med.140: 1037-1051, 2004

• Belford AM, Myles O, Myhand RC, Wang J, Magill A, Waselenko JK. Thrombotic Microangiopathy (TMA) and Stroke Due to Human Herpesvirus-6 (HHV-6) Reactivation in an Adult Receiving High-dose Melphalan with Autologous Peripheral Stem Cell Transplantation. Am J Hematol76:156-162, 2004

• Dainiak N., Waselenko, J.K, Armitage J.O.,  MacVittie T, Faress AM. The hematologist and radiation casualties. Hematology 2003 (Am Soc Hematol Ed Prog Book): 473-496.

• Waselenko JK, Burrows A, Nelson DA, Lucas M, Ekstrand J, Edenfield WJ, Myhand RC. Post-transplant interleukin 2 (IL2) in patients with low-grade lymphoid neoplasms previously treated with fludarabine associated with increased hematologic toxicity. Ann Hematol. 82: 552-557, 2003

• Waselenko J.K., Shinn C.A., Willis C.R., Flinn I.W., Grever M.R., Byrd J.C. Carboxyamido-triazole (CAI), a novel static signal transduction inhibitor induces apoptosis in human B-chronic lymphocytic leukemia cells. Leuk Lymphoma 42: 1049-1053, 2001

• Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Park K., Pearson M., Buj V., Waselenko J.K., Ling G, Grever M., Kunkel L., Flinn I.W.  Rituximab administered using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates significant activity. J Clin Oncol 19: 2153-64, 2001

• Waselenko J.K., Grever M.R., Shinn C.A., Flinn I.W., Byrd J.C.  Gemcitabine demonstrates selective in vitro activity in human B-cell chronic lymphocytic leukemia.  Leuk Res 25: 435-40, 2001

• Byrd J.C., Waselenko J.K., Keating M., Rai K., Grever M.R.  Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol 27:587-597, 2000

• Waselenko J,K., Grever M.R , Beer M, Lucas M,., Byrd J.C. Pentostatin (Nipent) and chlorambucil with GM-CSF support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.  Semin Oncol 27 (Suppl 5): 44-51, 2000

• Byrd J.C., Grever, M.R., Waselenko J,K., Willis C.R. Park K, Goodrich A, Lucas M.A. Shinn C, Flinn I.W.  Theophylline, pentostatin, (Nipent), and chlorambucil: A dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. Semin Oncol 27 (Suppl 5): 37-40, 2000

• Byrd J.C., Shinn C.A., Raji R., Willis C.R., Waselenko J.K., Flinn I.W., Dawson N.A., Grever M.R. Depsipeptide  (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-chronic lymphocytic leukemia cells.  Blood 94: 1401-8, 1999

• Byrd J.C., Waselenko J.K., Maneatis T.A., Ward F. T., Weickum R., White C.A.  Rituximab therapy in hematologic malignancy patients with circulating blood tumors: An association with increased infusion-related side effects and rapid tumor lysis.  J Clin Oncol 17: 791-795, 1999

• Byrd J.C., Shinn C.A., Bedi A., Waselenko J.K., Fuchs E.J., Lehman T., Nguyen P., Flinn I.W., Diehl L.F., Sausville E., Grever M.R.  Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence upon functional p53. Blood 92: 3804-3816, 1998.

• Waselenko J.K., Nace M.C., Alving B.A.  Women with thrombophilia: Assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy. Seminars in Thrombosis and Haemostasis 24 (Suppl 1): 33-39, 1998

• Tuttle R.M., Waselenko J.K., Yoseffi P, Weigand N, Martin R.K.  Preservation of nucleic acids for PCR after prolonged storage at room temperature.Diagn Mol Pathol 7: 302-9, 1998.

• Waselenko J.K., Flynn J.M., Byrd J.C. Stem cell transplantation in chronic lymphocytic leukemia: The time to design randomized studies has arrived.  Semin Oncol 26: 48-61, 1998

• Kenner J.R., Sperling L.C., Waselenko J.,  Dawson N., Sau P., Moul J.W.  Suramin Keratosis: A unique skin eruption in a patient receiving suramin for metastatic prostate cancer.  J Urol 158: 2245-2246, 1997.

• Waselenko J.K., Dawson N.A. Management of Progressive Metastatic Prostate Cancer. Oncology 11:1551-60, 1997.